Legend Biotech Corp Research and Development Expense
Legend Biotech Corp (LEGN) reported Research and Development Expense of $414.70 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-03-10
- Legend Biotech Corp research and development expense for the quarter ending 2025-12-31 was $101.33M, a 2.93% decline year-over-year.
- Legend Biotech Corp research and development expense for the quarter ending 2025-09-30 was $113.15M, a 18.45% increase year-over-year.
- Legend Biotech Corp research and development expense for the quarter ending 2025-06-30 was $98.30M, a 12.72% decline year-over-year.
- Legend Biotech Corp research and development expense for the quarter ending 2025-03-31 was $101.92M, a 0.95% increase year-over-year.
| Period end | Research And Development Expense 3 month | Research And Development Expense 6 month | Research And Development Expense 9 month | Research And Development Expense 12 month | Research And Development Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $101.33M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $214.47M derived: sum of 2 quarters · filed 2026-03-10 | $312.78M derived: sum of 3 quarters · filed 2026-03-10 | $414.70M 20-F · filed 2026-03-10 | |
| 2025-09-30 | $113.15M 6-K · filed 2025-11-12 | $211.45M derived: sum of 2 quarters · filed 2025-11-12 | $313.37M 6-K · filed 2025-11-12 | $417.76M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-06-30 | $98.30M 6-K · filed 2025-08-11 | $200.23M 6-K · filed 2025-08-11 | $304.61M derived: sum of 3 quarters · filed 2026-03-10 | $400.14M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-03-31 | $101.92M 6-K · filed 2025-05-13 | $206.31M derived: sum of 2 quarters · filed 2026-03-10 | $301.83M derived: sum of 3 quarters · filed 2026-03-10 | $414.46M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-12-31 | $104.39M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $199.91M derived: sum of 2 quarters · filed 2026-03-10 | $312.54M derived: sum of 3 quarters · filed 2026-03-10 | $413.50M 20-F · filed 2026-03-10 | $413.54M 20-F · filed 2025-03-11 |
| 2024-09-30 | $95.52M 6-K · filed 2025-11-12 | $208.15M derived: sum of 2 quarters · filed 2025-11-12 | $309.11M 6-K · filed 2025-11-12 | $414.78M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-06-30 | $112.63M 6-K · filed 2025-08-11 | $213.59M 6-K · filed 2025-08-11 | $319.25M derived: sum of 3 quarters · filed 2026-03-10 | $415.11M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-03-31 | $100.96M 6-K · filed 2025-05-13 | $206.63M derived: sum of 2 quarters · filed 2026-03-10 | $302.48M derived: sum of 3 quarters · filed 2026-03-10 | $398.27M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2023-12-31 | $105.67M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $201.52M derived: sum of 2 quarters · filed 2026-03-10 | $297.31M derived: sum of 3 quarters · filed 2026-03-10 | $382.20M 20-F · filed 2026-03-10 | $382.22M 20-F · filed 2024-03-19 |
| 2023-09-30 | $95.86M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | $191.65M derived: sum of 2 quarters · filed 2024-11-12 | $276.54M 6-K · filed 2024-11-12 | $357.29M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | $95.79M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | $180.68M 6-K · filed 2024-08-09 | $261.44M derived: sum of 3 quarters · filed 2025-03-11 | $365.95M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-03-31 | $84.89M 6-K · filed 2024-05-13 | $165.65M derived: sum of 2 quarters · filed 2025-03-11 | $270.16M derived: sum of 3 quarters · filed 2025-03-11 | ||
| 2022-12-31 | $80.76M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | $185.27M derived: sum of 2 quarters · filed 2025-03-11 | $335.65M 20-F · filed 2025-03-11 | ||
| 2022-09-30 | $104.52M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | $254.89M 6-K · filed 2023-11-20 | |||
| 2022-06-30 | $150.38M 6-K · filed 2023-08-15 | ||||
| 2021-12-31 | $313.35M 20-F · filed 2024-03-19 | ||||
| 2021-06-30 | $154.53M 6-K · filed 2021-08-23 | ||||
| 2020-12-31 | $232.16M 20-F · filed 2023-03-30 | ||||
| 2020-06-30 | $101.57M 6-K · filed 2021-08-23 | ||||
| 2019-12-31 | $161.94M 20-F/A · filed 2023-02-17 | ||||
| 2018-12-31 | $60.64M 20-F · filed 2021-04-02 |